Global Oncology Academy

Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
On the Frontlines of AML/ALL
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
- Charles Turck, PharmD, BCPS, BCCCP
- Lena Winestone, MD, MSHP
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
- Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®
Smarter Screening for Non-Small Cell Lung Cancer
- Jobelle Baldonado, MD
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
AudioAbstracts
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
- Ryan Quigley
Cosibelimab Delivers Durable Responses in Advanced CSCC
Cosibelimab Delivers Durable Responses in Advanced CSCC
Project Oncology®
Cosibelimab Delivers Durable Responses in Advanced CSCC
Recognizing High-Risk Profiles for NSCLC
Recognizing High-Risk Profiles for NSCLC
Project Oncology®
Recognizing High-Risk Profiles for NSCLC
- Jobelle Baldonado, MD
Expanding Molecular Testing in Community NSCLC Care
Expanding Molecular Testing in Community NSCLC Care
Project Oncology®
Expanding Molecular Testing in Community NSCLC Care
- Apar Kishor Ganti, MD, MS
Addressing Unmet Needs in First-Line mTNBC Care
Addressing Unmet Needs in First-Line mTNBC Care
On the Frontlines of Metastatic Breast Cancer
Addressing Unmet Needs in First-Line mTNBC Care
- Jennifer Caudle, DO, FACOFP
- Alexis Ann LeVee, MD

Medical News

Medical News
FDA Fast Track for AKY‑1189
02/25/2026
Read more
Medical News
Rising Early‑Onset Cancers: Global Patterns, Mortality Signals, and Screening Questions
02/24/2026
Read more
Medical News
Integration of TULA and BSPMs in a Secondary Care Bladder Cancer Pathway
02/24/2026
Read more
Medical News
Triple‑Phytochemical Nanoparticle for CRC: Formulation, In Vitro Release, Safety, and Gene‑Expression Signals
02/24/2026
Read more

See more news

CME/CE

The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
MinuteCE®
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
MinuteCE®
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
1.00 program credit
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
MinuteCE®
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
1.00 program credit
- Michiel van de Sande, MD, PhD
1.00 program credit

Clinical Practice

A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
- Geoffrey Oxnard, MD
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Project Oncology®
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Oncogenic Drivers in Never-Smokers with NSCLC
Oncogenic Drivers in Never-Smokers with NSCLC
Project Oncology®
Oncogenic Drivers in Never-Smokers with NSCLC
- Apar Kishor Ganti, MD, MS
Tracking Treatment Response: ctDNA Insights in MMR-p Colon Cancer
Tracking Treatment Response: ctDNA Insights in MMR-p Colon Cancer
Project Oncology®
Tracking Treatment Response: ctDNA Insights in MMR-p Colon Cancer
- Brian P. McDonough, MD, FAAFP
- Christopher T. Chen, MD

Programs

Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Project Oncology®
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
- Charles Turck, PharmD, BCPS, BCCCP
- Kelly McCann, MD, PhD
- Gregory Vidal, MD, PhD
Biomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
Biomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Biomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
- Maxwell Llyod, MD
- Ryan Quigley
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Project Oncology®
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Prioritizing Quality of Life in CRC: Key Surgical Considerations
Prioritizing Quality of Life in CRC: Key Surgical Considerations
On the Frontlines of Colorectal Cancer
Prioritizing Quality of Life in CRC: Key Surgical Considerations
- Ryan Quigley
- Thomas Cataldo, MD
- Sowmya Sharma, MD